|
1
|
Lane DP and Crawford LV: T antigen is
bound to a host protein in SV40-transformed cells. Nature.
278:261–263. 1979. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Linzer DI and Levine AJ: Characterization
of a 54K dalton cellular SV40 tumor antigen present in
SV40-transformed cells and uninfected embryonal carcinoma cells.
Cell. 17:43–52. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Levine AJ and Oren M: The first 30 years
of p53: Growing ever more complex. Nat Rev Cancer. 9:749–758. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tornesello ML, Annunziata C, Tornesello
AL, Buonaguro L and Buonaguro FM: Human Oncoviruses and p53 tumor
suppressor pathway deregulation at the origin of human cancers.
Cancers (Basel). 10:2132018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rotter V: p53, a transformation-related
cellular-encoded protein, can be used as a biochemical marker for
the detection of primary mouse tumor cells. Proc Natl Acad Sci USA.
80:2613–2617. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oren M and Levine AJ: Molecular cloning of
a cDNA specific for the murine p53 cellular tumor antigen. Proc
Natl Acad Sci USA. 80:56–59. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jenkins JR, Rudge K and Currie GA:
Cellular immortalization by a cDNA clone encoding the
transformation-associated phosphoprotein p53. Nature. 312:651–654.
1984. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eliyahu D, Michalovitz D and Oren M:
Overproduction of p53 antigen makes established cells highly
tumorigenic. Nature. 316:158–160. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Finlay CA, Hinds PW, Tan TH, Eliyahu D,
Oren M and Levine AJ: Activating mutations for transformation by
p53 produce a gene product that forms an hsc70-p53 complex with an
altered half-life. Mol Cell Biol. 8:531–539. 1988.PubMed/NCBI
|
|
10
|
Baker SJ, Fearon ER, Nigro JM, Hamilton
SR, Preisinger AC, Jessup JM, vanTuinen P, Ledbetter DH, Barker DF,
Nakamura Y, et al: Chromosome 17 deletions and p53 gene mutations
in colorectal carcinomas. Science. 244:217–221. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eliyahu D, Michalovitz D, Eliyahu S,
Pinhasi-Kimhi O and Oren M: Wild-type p53 can inhibit
oncogene-mediated focus formation. Proc Natl Acad Sci USA.
86:8763–8767. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Finlay CA, Hinds PW and Levine AJ: The p53
proto-oncogene can act as a suppressor of transformation. Cell.
57:1083–1093. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schneider K, Zelley K, Nichols KE and
Garber J: Li-Fraumeni Syndrome. GeneReviews(®). Adam MP, Feldman J,
Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW and Amemiya A:
University of Washington; Seattle, WA: 1993
|
|
14
|
Fortuno C, Feng BJ, Carroll C, Innella G,
Kohlmann W, Lázaro C, Br unet J, Feliubadaló L, Iglesias S,
Menéndez M, et al: Cancer risks associated with TP53 pathogenic
variants: Maximum likelihood analysis of extended pedigrees for
diagnosis of first cancers beyond the Li-Fraumeni Syndrome
Spectrum. JCO Precis Oncol. 8:e23004532024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Malkin D: Li-fraumeni syndrome. Genes
Cancer. 2:475–484. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Levine AJ: p53: 800 million years of
evolution and 40 years of discovery. Nat Rev Cancer. 20:471–480.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Y, Su Z, Tavana O and Gu W:
Understanding the complexity of p53 in a new era of tumor
suppression. Cancer Cell. 42:946–967. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang H, Guo M, Wei H and Chen Y: Targeting
p53 pathways: Mechanisms, structures, and advances in therapy.
Signal Transduct Target Ther. 8:922023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Indeglia A and Murphy ME: Elucidating the
chain of command: Our current understanding of critical target
genes for p53-mediated tumor suppression. Crit Rev Biochem Mol
Biol. 59:128–138. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Olivier M, Hussain SP, Caron de Fromentel
C, Hainaut P and Harris CC: TP53 mutation spectra and load: A tool
for generating hypotheses on the etiology of cancer. IARC Sci Publ.
(157): 247–270. 2004.PubMed/NCBI
|
|
22
|
Tornesello ML, Buonaguro L, Tatangelo F,
Botti G, Izzo F and Buonaguro FM: Mutations in TP53, CTNNB1 and
PIK3CA genes in hepatocellular carcinoma associated with hepatitis
B and hepatitis C virus infections. Genomics. 102:74–83. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hainaut P and Pfeifer GP: Somatic TP53
Mutations in the Era of Genome Sequencing. Cold Spring Harb
Perspect Med. 6:a0261792016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sammons MA, Nguyen TT, McDade SS and
Fischer M: Tumor suppressor p53: From engaging DNA to target gene
regulation. Nucleic Acids Res. 48:8848–8869. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kubbutat MH, Jones SN and Vousden KH:
Regulation of p53 stability by Mdm2. Nature. 387:299–303. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Haupt Y, Maya R, Kazaz A and Oren M: Mdm2
promotes the rapid degradation of p53. Nature. 387:296–299. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Raj N and Attardi LD: The Transactivation
Domains of the p53 Protein. Cold Spring Harb Perspect Med.
7:a0260472017. View Article : Google Scholar
|
|
28
|
Krois AS, Park S, Martinez-Yamout MA,
Dyson HJ and Wright PE: Mapping Interactions of the Intrinsically
Disordered C-Terminal Regions of Tetrameric p53 by Segmental
Isotope Labeling and NMR. Biochemistry. 61:2709–2719. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kruse JP and Gu W: SnapShot: p53
posttranslational modifications. Cell. 133:930–930.e1. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brady CA, Jiang D, Mello SS, Johnson TM,
Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ,
McLaughlin ME, et al: Distinct p53 transcriptional programs dictate
acute DNA-damage responses and tumor suppression. Cell.
145:571–583. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Riley T, Sontag E, Chen P and Levine A:
Transcriptional control of human p53-regulated genes. Nat Rev Mol
Cell Biol. 9:402–412. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
el-Deiry WS, Kern SE, Pietenpol JA,
Kinzler KW and Vogelstein B: Definition of a consensus binding site
for p53. Nat Genet. 1:45–49. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Halazonetis TD and Kandil AN:
Conformational shifts propagate from the oligomerization domain of
p53 to its tetrameric DNA binding domain and restore DNA binding to
select p53 mutants. EMBO J. 12:5057–5064. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gu W and Roeder RG: Activation of p53
sequence-specific DNA binding by acetylation of the p53 C-terminal
domain. Cell. 90:595–606. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hernández Borrero LJ and El-Deiry WS:
Tumor suppressor p53: Biology, signaling pathways, and therapeutic
targeting. Biochim Biophys Acta Rev Cancer. 1876:1885562021.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jenkins LM, Durell SR, Mazur SJ and
Appella E: p53 N-terminal phosphorylation: A defining layer of
complex regulation. Carcinogenesis. 33:1441–1449. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lill NL, Grossman SR, Ginsberg D, DeCaprio
J and Livingston DM: Binding and modulation of p53 by p300/CBP
coactivators. Nature. 387:823–827. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gostissa M, Hengstermann A, Fogal V, Sandy
P, Schwarz SE, Scheffner M and Del Sal G: Activation of p53 by
conjugation to the ubiquitin-like protein SUMO-1. EMBO J.
18:6462–6471. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Stindt MH, Carter S, Vigneron AM, Ryan KM
and Vousden KH: MDM2 promotes SUMO-2/3 modification of p53 to
modulate transcriptional activity. Cell Cycle. 10:3176–3188. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
West LE and Gozani O: Regulation of p53
function by lysine methylation. Epigenomics. 3:361–369. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Laptenko O, Shiff I, Freed-Pastor W,
Zupnick A, Mattia M, Freulich E, Shamir I, Kadouri N, Kahan T,
Manfredi J, et al: The p53 C terminus controls site-specific DNA
binding and promotes structural changes within the central DNA
binding domain. Mol Cell. 57:1034–1046. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shirangi TR, Zaika A and Moll UM: Nuclear
degradation of p53 occurs during down-regulation of the p53
response after DNA damage. FASEB J. 16:420–422. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhu G, Pan C, Bei JX, Li B, Liang C, Xu Y
and Fu X: Mutant p53 in cancer progression and targeted therapies.
Front Oncol. 10:5951872020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Donehower LA, Soussi T, Korkut A, Liu Y,
Schultz A, Cardenas M, Li X, Babur O, Hsu TK, Lichtarge O, et al:
Integrated Analysis of TP53 gene and pathway alterations in the
cancer genome atlas. Cell Rep. 28:1370–1384 e5. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin
X, Lei H, Wang J, Xie X, Cheng B, et al: Mutant p53 in cancer: From
molecular mechanism to therapeutic modulation. Cell Death Dis.
13:9742022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shirole NH, Pal D, Kastenhuber ER, Senturk
S, Boroda J, Pisterzi P, Miller M, Munoz G, Anderluh M, Ladanyi M,
et al: TP53 exon-6 truncating mutations produce separation of
function isoforms with pro-tumorigenic functions. Elife.
5:e179292016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Castrogiovanni C, Waterschoot B, De Backer
O and Dumont P: Serine 392 phosphorylation modulates p53
mitochondrial translocation and transcription-independent
apoptosis. Cell Death Differ. 25:190–203. 2018. View Article : Google Scholar :
|
|
48
|
Sonego M, Schiappacassi M, Lovisa S,
Dall'Acqua A, Bagnoli M, Lovat F, Libra M, D'Andrea S, Canzonieri
V, Militello L, et al: Stathmin regulates mutant p53 stability and
transcriptional activity in ovarian cancer. EMBO Mol Med.
5:707–722. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang D, Nakayama M, Hong CP, Oshima H and
Oshima M: Gain-of-Function p53 mutation acts as a genetic switch
for TGFβ signaling-induced epithelial-to-mesenchymal transition in
intestinal tumors. Cancer Res. 84:56–68. 2024. View Article : Google Scholar
|
|
50
|
Alvarado-Ortiz E, de la Cruz-López KG,
Becerril-Rico J, Sarabia-Sánchez MA, Ortiz-Sánchez E and
García-Carrancá A: Mutant p53 Gain-of-Function: Role in cancer
development, progression, and therapeutic approaches. Front Cell
Dev Biol. 8:6076702021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kastenhuber ER and Lowe SW: Putting p53 in
Context. Cell. 170:1062–1078. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Boettcher S, Miller PG, Sharma R, McConkey
M, Leventhal M, Krivtsov AV, Giacomelli AO, Wong W, Kim J, Chao S,
et al: A dominant-negative effect drives selection of TP53 missense
mutations in myeloid malignancies. Science. 365:599–604. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Aubrey BJ, Janic A, Chen Y, Chang C,
Lieschke EC, Diepstraten ST, Kueh AJ, Bernardini JP, Dewson G,
O'Reilly LA, et al: Mutant TRP53 exerts a target gene-selective
dominant-negative effect to drive tumor development. Genes Dev.
32:1420–1429. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Martins CP, Brown-Swigart L and Evan GI:
Modeling the therapeutic efficacy of p53 restoration in tumors.
Cell. 127:1323–1334. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Shchors K, Persson AI, Rostker F, Tihan T,
Lyubynska N, Li N, Swigart LB, Berger MS, Hanahan D, Weiss WA and
Evan GI: Using a preclinical mouse model of high-grade astrocytoma
to optimize p53 restoration therapy. Proc Natl Acad Sci USA.
110:E1480–E1489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ventura A, Kirsch DG, McLaughlin ME,
Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R
and Jacks T: Restoration of p53 function leads to tumour regression
in vivo. Nature. 445:661–665. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Baugh EH, Ke H, Levine AJ, Bonneau RA and
Chan CS: Why are there hotspot mutations in the TP53 gene in human
cancers? Cell Death Differ. 25:154–160. 2018. View Article : Google Scholar :
|
|
58
|
Yang C, Lou G and Jin WL: The arsenal of
TP53 mutants therapies: Neoantigens and bispecific antibodies.
Signal Transduct Target Ther. 6:2192021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
McCann JJ, Vasilevskaya IA, McNair C,
Gallagher P, Neupane NP, de Leeuw R, Shafi AA, Dylgjeri E, Mandigo
AC, Schiewer MJ and Knudsen KE: Mutant p53 elicits
context-dependent pro-tumorigenic phenotypes. Oncogene. 41:444–458.
2022. View Article : Google Scholar :
|
|
60
|
Xiong S, Chachad D, Zhang Y,
Gencel-Augusto J, Sirito M, Pant V, Yang P, Sun C, Chau G, Qi Y, et
al: Differential Gain-of-Function Activity of Three p53 Hotspot
mutants in vivo. Cancer Res. 82:1926–1936. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Rasquinha JA, Bej A, Dutta S and Mukherjee
S: Intrinsic differences in backbone dynamics between wild type and
DNA-Contact Mutants of the p53 DNA binding domain revealed by
nuclear magnetic resonance spectroscopy. Biochemistry.
56:4962–4971. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Salari A, Thomay K, Lentes J, Ebersold J,
Hagedorn M, Skawran B, Davenport C, Schambach A, Schlegelberger B
and Göhring G: Effect of TP53 contact and conformational mutations
on cell survival and erythropoiesis of human hematopoietic stem
cells in a long term culture model. Oncotarget. 9:29869–29876.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Pfister NT and Prives C: Transcriptional
regulation by wild-type and cancer-related mutant forms of p53.
Cold Spring Harb Perspect Med. 7:a0260542017. View Article : Google Scholar
|
|
64
|
Di Agostino S, Strano S, Emiliozzi V,
Zerbini V, Mottolese M, Sacchi A, Blandino G and Piaggio G: Gain of
function of mutant p53: The mutant p53/NF-Y protein complex reveals
an aberrant transcriptional mechanism of cell cycle regulation.
Cancer Cell. 10:191–202. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Di Agostino S, Sorrentino G, Ingallina E,
Valenti F, Ferraiuolo M, Bicciato S, Piazza S, Strano S, Del Sal G
and Blandino G: YAP enhances the pro-proliferative transcriptional
activity of mutant p53 proteins. EMBO Rep. 17:188–201. 2016.
View Article : Google Scholar
|
|
66
|
Zhang J, Sun W, Kong X, Zhang Y, Yang HJ,
Ren C, Jiang Y, Chen M and Chen X: Mutant p53 antagonizes
p63/p73-mediated tumor suppression via Notch1. Proc Natl Acad Sci
USA. 116:24259–24267. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Morselli E, Tasdemir E, Maiuri MC,
Galluzzi L, Kepp O, Criollo A, Vicencio JM, Soussi T and Kroemer G:
Mutant p53 protein localized in the cytoplasm inhibits autophagy.
Cell Cycle. 7:3056–3061. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Wang Z, Burigotto M, Ghetti S, Vaillant F,
Tan T, Capaldo BD, Palmieri M, Hirokawa Y, Tai L, Simpson DS, et
al: Loss-of-Function but not gain-of-function properties of mutant
TP53 are critical for the proliferation, survival, and metastasis
of a broad range of cancer cells. Cancer Discov. 14:362–379. 2024.
View Article : Google Scholar :
|
|
69
|
Roszkowska KA, Piecuch A, Sady M, Gajewski
Z and Flis S: Gain of Function (GOF) Mutant p53 in cancer-current
therapeutic approaches. Int J Mol Sci. 23:132872022. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Bougeard G, Sesboue R, Baert-Desurmont S,
Martin C, Tinat J, Brugières L, Chompret A, de Paillerets BB,
Stoppa-Lyonnet D, Bonaïti-Pellié C, et al: Molecular basis of the
Li-Fraumeni syndrome: An update from the French LFS families. J Med
Genet. 45:535–538. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Levine AJ: Spontaneous and inherited TP53
genetic alterations. Oncogene. 40:5975–5983. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Robles AI, Jen J and Harris CC: Clinical
Outcomes of TP53 mutations in cancers. Cold Spring Harb Perspect
Med. 6:a0262942016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Sampath J, Sun D, Kidd VJ, Grenet J,
Gandhi A, Shapiro LH, Wang Q, Zambetti GP and Schuetz JD: Mutant
p53 cooperates with ETS and selectively up-regulates human MDR1 not
MRP1. J Biol Chem. 276:39359–39367. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Bossi G, Lapi E, Strano S, Rinaldo C,
Blandino G and Sacchi A: Mutant p53 gain of function: reduction of
tumor malignancy of human cancer cell lines through abrogation of
mutant p53 expression. Oncogene. 25:304–309. 2006. View Article : Google Scholar
|
|
75
|
Wang Q, Wei F, Lv G, Li C, Liu T,
Hadjipanayis CG, Zhang G, Hao C and Bellail AC: The association of
TP53 mutations with the resistance of colorectal carcinoma to the
insulin-like growth factor-1 receptor inhibitor picropodophyllin.
BMC Cancer. 13:5212013. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Wong RP, Tsang WP, Chau PY, Co NN, Tsang
TY and Kwok TT: p53-R273H gains new function in induction of drug
resistance through down-regulation of procaspase-3. Mol Cancer
Ther. 6:1054–1061. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Huang Y, Liu N, Liu J, Liu Y, Zhang C,
Long S, Luo G, Zhang L and Zhang Y: Mutant p53 drives cancer
chemotherapy resistance due to loss of function on activating
transcription of PUMA. Cell Cycle. 18:3442–3455. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
O'Connor PM, Jackman J, Bae I, Myers TG,
Fan S, Mutoh M, Scudiero DA, Monks A and Sausville EA:
Characterization of the p53 tumor suppressor pathway in cell lines
of the National Cancer Institute anticancer drug screen and
correlations with the growth-inhibitory potency of 123 anticancer
agents. Cancer Res. 57:4285–4300. 1997.PubMed/NCBI
|
|
79
|
Kong X, Yu D, Wang Z and Li S:
Relationship between p53 status and the bioeffect of ionizing
radiation. Oncol Lett. 22:6612021. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Hassin O and Oren M: Drugging p53 in
cancer: One protein, many targets. Nat Rev Drug Discov. 22:127–144.
2023. View Article : Google Scholar
|
|
81
|
Peuget S, Zhou X and Selivanova G:
Translating p53-based therapies for cancer into the clinic. Nat Rev
Cancer. 24:192–215. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Hu J, Cao J, Topatana W, Juengpanich S, Li
S, Zhang B, Shen J, Cai L, Cai X and Chen M: Targeting mutant p53
for cancer therapy: Direct and indirect strategies. J Hematol
Oncol. 14:1572021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Gu H, Wang X, Rao S, Wang J, Zhao J, Ren
FL, Mu R, Yang Y, Qi Q, Liu W, et al: Gambogic acid mediates
apoptosis as a p53 inducer through down-regulation of mdm2 in
wild-type p53-expressing cancer cells. Mol Cancer Ther.
7:3298–3305. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Wang J, Zhao Q, Qi Q, Gu HY, Rong JJ, Mu
R, Zou MJ, Tao L, You QD and Guo QL: Gambogic acid-induced
degradation of mutant p53 is mediated by proteasome and related to
CHIP. J Cell Biochem. 112:509–519. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Pan H, Lu LY, Wang XQ, Li BX, Kelly K and
Lin HS: Gambogic acid induces cell apoptosis and inhibits MAPK
Pathway in PTEN(-/-)/p53(-/-) prostate cancer cells in vitro and ex
vivo. Chin J Integr Med. 24:109–116. 2018. View Article : Google Scholar
|
|
86
|
Garufi A, Pistritto G, Cirone M and
D'Orazi G: Reactivation of mutant p53 by capsaicin, the major
constituent of peppers. J Exp Clin Cancer Res. 35:1362016.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Padmanabhan A, Candelaria N, Wong KK,
Nikolai BC, Lonard DM, O'Malley BW and Richards JS: USP15-dependent
lysosomal pathway controls p53-R175H turnover in ovarian cancer
cells. Nat Commun. 9:12702018. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Zhang S, Zhou L, Hong B, van den Heuvel
AP, Prabhu VV, Warfel NA, Kline CL, Dicker DT, Kopelovich L and
El-Deiry WS: Small-Molecule NSC59984 Restores p53 pathway signaling
and antitumor effects against colorectal cancer via p73 activation
and degradation of mutant p53. Cancer Res. 75:3842–3852. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Jhaveri K and Modi S: Ganetespib: Research
and clinical development. Onco Targets Ther. 8:1849–1858.
2015.PubMed/NCBI
|
|
90
|
Alexandrova EM, Xu S and Moll UM:
Ganetespib synergizes with cyclophosphamide to improve survival of
mice with autochthonous tumors in a mutant p53-dependent manner.
Cell Death Dis. 8:e26832017. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Wong WW, Dimitroulakos J, Minden MD and
Penn LZ: HMG-CoA reductase inhibitors and the malignant cell: the
statin family of drugs as triggers of tumor-specific apoptosis.
Leukemia. 16:508–519. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Kornblau SM, Banker DE, Stirewalt D, Shen
D, Lemker E, Verstovsek S, Estrov Z, Faderl S, Cortes J, Beran M,
et al: Blockade of adaptive defensive changes in cholesterol uptake
and synthesis in AML by the addition of pravastatin to idarubicin +
high-dose Ara-C: A phase 1 study. Blood. 109:2999–3006. 2007.
View Article : Google Scholar
|
|
93
|
Parrales A, Ranjan A, Iyer SV, Padhye S,
Weir SJ, Roy A and Iwakuma T: DNAJA1 controls the fate of misfolded
mutant p53 through the mevalonate pathway. Nat Cell Biol.
18:1233–1243. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Martirosyan A, Clendening JW, Goard CA and
Penn LZ: Lovastatin induces apoptosis of ovarian cancer cells and
synergizes with doxorubicin: Potential therapeutic relevance. BMC
Cancer. 10:1032010. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Li D, Marchenko ND and Moll UM: SAHA shows
preferential cytotoxicity in mutant p53 cancer cells by
destabilizing mutant p53 through inhibition of the HDAC6-Hsp90
chaperone axis. Cell Death Differ. 18:1904–1913. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Durairaj G, Demir O, Lim B, Baronio R,
Tifrea D, Hall LV, DeForest JC, Lauinger L, Jebril Fallatah MM, Yu
C, et al: Discovery of compounds that reactivate p53 mutants in
vitro and in vivo. Cell Chem Biol. 29:1381–1395 e13. 2022.
View Article : Google Scholar
|
|
97
|
Di Agostino S, Fontemaggi G, Strano S,
Blandino G and D'Orazi G: Targeting mutant p53 in cancer: The
latest insights. J Exp Clin Cancer Res. 38:2902019. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Huang Y, Jiao Z, Fu Y, Hou Y, Sun J, Hu F,
Yu S, Gong K, Liu Y and Zhao G: An overview of the functions of p53
and drugs acting either on wild- or mutant-type p53. Eur J Med
Chem. 265:1161212024. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Bykov VJ, Issaeva N, Shilov A, Hultcrantz
M, Pugacheva E, Chumakov P, Bergman J, Wiman KG and Selivanova G:
Restoration of the tumor suppressor function to mutant p53 by a
low-molecular-weight compound. Nat Med. 8:282–288. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Saha MN, Jiang H, Yang Y, Reece D and
Chang H: PRIMA-1Met/APR-246 displays high antitumor activity in
multiple myeloma by induction of p73 and Noxa. Mol Cancer Ther.
12:2331–2341. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Furukawa H, Makino T, Yamasaki M, Tanaka
K, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S,
Mori M and Doki Y: PRIMA-1 induces p53-mediated apoptosis by
upregulating Noxa in esophageal squamous cell carcinoma with TP53
missense mutation. Cancer Sci. 109:412–421. 2018. View Article : Google Scholar
|
|
102
|
Zandi R, Selivanova G, Christensen CL,
Gerds TA, Willumsen BM and Poulsen HS: PRIMA-1Met/APR-246 induces
apoptosis and tumor growth delay in small cell lung cancer
expressing mutant p53. Clin Cancer Res. 17:2830–2841. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Li XL, Zhou J, Chan ZL, Chooi JY, Chen ZR
and Chng WJ: PRIMA-1met (APR-246) inhibits growth of colorectal
cancer cells with different p53 status through distinct mechanisms.
Oncotarget. 6:36689–36699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Sallman DA, DeZern AE, Garcia-Manero G,
Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A,
McGraw KL, et al: Eprenetapopt (APR-246) and Azacitidine in
TP53-Mutant myelodysplastic syndromes. J Clin Oncol. 39:1584–1594.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Cluzeau T, Sebert M, Rahmé R, Cuzzubbo S,
Lehmann-Che J, Madelaine I, Peterlin P, Bève B, Attalah H, Chermat
F, et al: Eprenetapopt Plus Azacitidine in TP53-Mutated
myelodysplastic syndromes and acute myeloid leukemia: A phase II
study by the groupe francophone des myélodysplasies (GFM). J Clin
Oncol. 39:1575–1583. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Grellety T, Laroche-Clary A, Chaire V,
Lagarde P, Chibon F, Neuville A and Italiano A: PRIMA-1(MET)
induces death in soft-tissue sarcomas cell independent of p53. BMC
Cancer. 15:6842015. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Aggarwal M, Saxena R, Sinclair E, Fu Y,
Jacobs A, Dyba M, Wang X, Cruz I, Berry D, Kallakury B, et al:
Reactivation of mutant p53 by a dietary-related compound phenethyl
isothiocyanate inhibits tumor growth. Cell Death Differ.
23:1615–1627. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Aggarwal M, Saxena R, Asif N, Sinclair E,
Tan J, Cruz I, Berry D, Kallakury B, Pham Q, Wang TTY and Chung FL:
p53 mutant-type in human prostate cancer cells determines the
sensitivity to phenethyl isothiocyanate induced growth inhibition.
J Exp Clin Cancer Res. 38:3072019. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Dumbrava ECJ, Tolcher ML, Shapiro AW,
Thompson G, El-Khoueiry JA, Vandross AB, Kummar AL, Parikh S,
Munster AR, Daly PM, et al: First-in-human study of PC14586, a
small molecule structural corrector of Y220C mutant p53, in
patients with advanced solid tumors harboring a TP53 Y220C
mutation. J Clin Oncol. 40:12022. View Article : Google Scholar
|
|
110
|
Chen S, Wu JL, Liang Y, Tang YG, Song HX,
Wu LL, Xing YF, Yan N, Li YT, Wang ZY, et al: Arsenic trioxide
rescues structural p53 mutations through a cryptic allosteric site.
Cancer Cell. 39:225–239.e8. 2021. View Article : Google Scholar
|
|
111
|
Tang Y, Song H, Wang Z, Xiao S, Xiang X,
Zhan H, Wu L, Wu J, Xing Y, Tan Y, et al: Repurposing antiparasitic
antimonials to noncovalently rescue temperature-sensitive p53
mutations. Cell Rep. 39:1106222022. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Lindemann A, Patel AA, Silver NL, Tang L,
Liu Z, Wang L, Tanaka N, Rao X, Takahashi H, Maduka NK, et al:
COTI-2, A novel thiosemicarbazone derivative, exhibits antitumor
activity in HNSCC through p53-dependent and -independent
Mechanisms. Clin Cancer Res. 25:5650–5662. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Issaeva N, Bozko P, Enge M, Protopopova M,
Verhoef LG, Masucci M, Pramanik A and Selivanova G: Small molecule
RITA binds to p53, blocks p53-HDM-2 interaction and activates p53
function in tumors. Nat Med. 10:1321–1328. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Zhao CY, Grinkevich VV, Nikulenkov F, Bao
W and Selivanova G: Rescue of the apoptotic-inducing function of
mutant p53 by small molecule RITA. Cell Cycle. 9:1847–1855. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Burmakin M, Shi Y, Hedström E, Kogner P
and Selivanova G: Dual targeting of wild-type and mutant p53 by
small molecule RITA results in the inhibition of N-Myc and key
survival oncogenes and kills neuroblastoma cells in vivo and in
vitro. Clin Cancer Res. 19:5092–5103. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Foster BA, Coffey HA, Morin MJ and
Rastinejad F: Pharmacological rescue of mutant p53 conformation and
function. Science. 286:2507–2510. 1999. View Article : Google Scholar
|
|
117
|
Takimoto R, Wang W, Dicker DT, Rastinejad
F, Lyssikatos J and el-Deiry WS: The mutant p53-conformation
modifying drug, CP-31398, can induce apoptosis of human cancer
cells and can stabilize wild-type p53 protein. Cancer Biol Ther.
1:47–55. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Wang W, Takimoto R, Rastinejad F and
El-Deiry WS: Stabilization of p53 by CP-31398 inhibits
ubiquitination without altering phosphorylation at serine 15 or 20
or MDM2 binding. Mol Cell Biol. 23:2171–2181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
He XX, Zhang YN, Yan JW, Yan JJ, Wu Q and
Song YH: CP-31398 inhibits the growth of p53-mutated liver cancer
cells in vitro and in vivo. Tumour Biol. 37:807–815. 2016.
View Article : Google Scholar
|
|
120
|
He X, Kong X, Yan J, Zhang Y, Wu Q, Chang
Y, Shang H, Dou Q, Song Y and Liu F: CP-31398 prevents the growth
of p53-mutated colorectal cancer cells in vitro and in vivo. Tumour
Biol. 36:1437–1444. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Arihara Y, Takada K, Kamihara Y, Hayasaka
N, Nakamura H, Murase K, Ikeda H, Iyama S, Sato T, Miyanishi K, et
al: Small molecule CP-31398 induces reactive oxygen
species-dependent apoptosis in human multiple myeloma. Oncotarget.
8:65889–65899. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Liu X, Wilcken R, Joerger AC, Chuckowree
IS, Amin J, Spencer J and Fersht AR: Small molecule induced
reactivation of mutant p53 in cancer cells. Nucleic Acids Res.
41:6034–6044. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Yu X, Vazquez A, Levine AJ and Carpizo DR:
Allele-specific p53 mutant reactivation. Cancer Cell. 21:614–625.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Blanden AR, Yu X, Blayney AJ, Demas C, Ha
JH, Liu Y, Withers T, Carpizo DR and Loh SN: Zinc shapes the
folding landscape of p53 and establishes a pathway for reactivating
structurally diverse cancer mutants. Elife. 9:e614872020.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Yu X, Blanden A, Tsang AT, Zaman S, Liu Y,
Gilleran J, Bencivenga AF, Kimball SD, Loh SN and Carpizo DR:
Thiosemicarbazones functioning as zinc metallochaperones to
reactivate mutant p53. Mol Pharmacol. 91:567–575. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Alexandrova EM, Yallowitz AR, Li D, Xu S,
Schulz R, Proia DA, Lozano G, Dobbelstein M and Moll UM: Improving
survival by exploiting tumour dependence on stabilized mutant p53
for treatment. Nature. 523:352–356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Shi XY, Ding W, Li TQ, Zhang YX and Zhao
SC: Histone Deacetylase (HDAC) inhibitor, suberoylanilide
hydroxamic acid (SAHA), induces apoptosis in prostate cancer cell
lines via the Akt/FOXO3a signaling pathway. Med Sci Monit.
23:5793–5802. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Panicker J, Li Z, McMahon C, Sizer C,
Steadman K, Piekarz R, Bates SE and Thiele CJ: Romidepsin
(FK228/depsipeptide) controls growth and induces apoptosis in
neuroblastoma tumor cells. Cell Cycle. 9:1830–1838. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen
DM, Chen GA and Schrump DS: Modulation of p53, ErbB1, ErbB2, and
Raf-1 expression in lung cancer cells by depsipeptide FR901228. J
Natl Cancer Inst. 94:504–513. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Lo YH, Kolahi KS, Du Y, Chang CY,
Krokhotin A, Nair A, Sobba WD, Karlsson K, Jones SJ, Longacre TA,
et al: A CRISPR/Cas9-Engineered ARID1A-Deficient human gastric
cancer organoid model reveals essential and nonessential modes of
oncogenic transformation. Cancer Discov. 11:1562–1581. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Geisinger JM and Stearns T: CRISPR/Cas9
treatment causes extended TP53-dependent cell cycle arrest in human
cells. Nucleic Acids Res. 48:9067–9081. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Alvarez MM, Biayna J and Supek F:
TP53-dependent toxicity of CRISPR/Cas9 cuts is differential across
genomic loci and can confound genetic screening. Nat Commun.
13:45202022. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Hsiue EH, Wright KM, Douglass J, Hwang MS,
Mog BJ, Pearlman AH, Paul S, DiNapoli SR, Konig MF, Wang Q, et al:
Targeting a neoantigen derived from a common TP53 mutation.
Science. 371:eabc86972021. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Wang Z, Strasser A and Kelly GL: Should
mutant TP53 be targeted for cancer therapy? Cell Death Differ.
29:911–920. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Olivier M, Hollstein M and Hainaut P: TP53
mutations in human cancers: Origins, consequences, and clinical
use. Cold Spring Harb Perspect Biol. 2:a0010082010. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Chatterjee K, Das P, Chattopadhyay NR, Mal
S and Choudhuri T: The interplay between Epstein-Bar virus (EBV)
with the p53 and its homologs during EBV associated malignancies.
Heliyon. 5:e026242019. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Martinez-Zapien D, Ruiz FX, Poirson J,
Mitschler A, Ramirez J, Forster A, Cousido-Siah A, Masson M, Vande
Pol S, Podjarny A, et al: Structure of the E6/E6AP/p53 complex
required for HPV-mediated degradation of p53. Nature. 529:541–545.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Lan KH, Sheu ML, Hwang SJ, Yen SH, Chen
SY, Wu JC, Wang YJ, Kato N, Omata M, Chang FY and Lee SD: HCV NS5A
interacts with p53 and inhibits p53-mediated apoptosis. Oncogene.
21:4801–4811. 2002. View Article : Google Scholar : PubMed/NCBI
|
